RUBYnanomed was founded in 2018 and aims to bring lab discoveries to the clinical market. RUBYnanomed focusses on the non-invasive monitoring of cancer progression, as cancer is a major cause of death worldwide that caused 9.6 million deaths in 2018, and 90 % of those are due to metastasis. We have developed a precise cancer snapshot tool, the RUBYchipTM, a microfluidic device for isolating all types of circulating tumour cells (CTCs) from unprocessed whole blood. Currently, RUBYnanomed is running pre-clinical trials at 8 hospitals for 5 different types of cancer in different countries in Europe.